ES2139591T3 - Asialoglicoproteinas del virus de la hepatitis c. - Google Patents
Asialoglicoproteinas del virus de la hepatitis c.Info
- Publication number
- ES2139591T3 ES2139591T3 ES92900091T ES92900091T ES2139591T3 ES 2139591 T3 ES2139591 T3 ES 2139591T3 ES 92900091 T ES92900091 T ES 92900091T ES 92900091 T ES92900091 T ES 92900091T ES 2139591 T3 ES2139591 T3 ES 2139591T3
- Authority
- ES
- Spain
- Prior art keywords
- hcv
- asialoglycoprotein
- region
- expressed
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 10
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108010002913 Asialoglycoproteins Proteins 0.000 abstract 7
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- 230000009450 sialylation Effects 0.000 abstract 2
- 102000009112 Mannose-Binding Lectin Human genes 0.000 abstract 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 abstract 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 239000004020 conductor Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 210000002288 golgi apparatus Anatomy 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Una asialoglicoproteína del virus de la hepatitis C (HCV) seleccionada entre una asialigricoproteína expresada en la región E1 del HCV y una asialoglicoproteína expresada en la región E2 del HCV, y agregados de las mismas, pudiéndose obtener dicha asialoglicoproteína mediante el método que comprende las etapas de: (i) cultivar una célula hospedante de mamífero tranformada con un gen estructural que codifica una asialoglicoproteína de HCV expresada en la región E1 de HCV, de la región E2 de HCV o de ambas, en un medio de cultivo adecuado, estando dicho gen estructural unido a una secuencia que codifica un conductor de la secreción que dirige a la asialoglicoproteína hacia el retículo endoplásmico; (ii) provocar la expresión de dicho gen estructural y conductor de la secreción, bajo condiciones que inhiben la sialilación; en el que dichas condiciones que inhiben la sialilación comprenden inhibir el transporte de las glicoproteínas desde el retículo endoplásmico hacia el aparato de Golgi de las células; y (iii) aislar dicha asialoglicoproteína de HCV del cultivo celular peoniendo en contacto dicha asialoglicoproteína de HCV con una proteína de unión a manosa, específica para glicoproteínas terminadas en manosa, en la que menos de aproximadamente 10% de los carbohidratos N-unidos totales son ácido siálico.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US611419 | 1984-05-17 | ||
| US61141990A | 1990-11-08 | 1990-11-08 | |
| US61196590A | 1990-11-08 | 1990-11-08 | |
| US75888091A | 1991-09-13 | 1991-09-13 | |
| US758880 | 1991-09-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2139591T3 true ES2139591T3 (es) | 2000-02-16 |
| ES2139591T5 ES2139591T5 (es) | 2007-08-01 |
Family
ID=27417050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92900091T Expired - Lifetime ES2139591T5 (es) | 1990-11-08 | 1991-11-07 | Asialoglicoproteinas del virus de la hepatitis c. |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP0556292B2 (es) |
| JP (8) | JPH06504431A (es) |
| AT (1) | ATE188220T1 (es) |
| AU (1) | AU668078B2 (es) |
| CA (2) | CA2095521C (es) |
| CZ (1) | CZ289006B6 (es) |
| DE (1) | DE69131882T3 (es) |
| DK (2) | DK0842947T4 (es) |
| ES (1) | ES2139591T5 (es) |
| FI (1) | FI107803B (es) |
| GR (1) | GR3032771T3 (es) |
| HU (2) | HU227498B1 (es) |
| NO (2) | NO304380B1 (es) |
| PT (2) | PT99466B (es) |
| RO (1) | RO115446B1 (es) |
| SK (3) | SK285623B6 (es) |
| WO (1) | WO1992008734A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274148B1 (en) * | 1990-11-08 | 2001-08-14 | Chiron Corporation | Hepatitis C virus asialoglycoproteins |
| JP3158177B2 (ja) * | 1991-10-08 | 2001-04-23 | 国立感染症研究所長 | Ｃ型肝炎診断薬 |
| EP0627000B1 (en) * | 1992-01-31 | 2003-10-29 | Abbott Laboratories | Mammalian expression systems for hcv proteins |
| UA39944C2 (uk) * | 1992-07-07 | 2001-07-16 | Чірон Корпорейшн | Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі |
| EP1421951A3 (en) | 1993-05-12 | 2005-10-05 | Chiron Corporation | Conserved motif of hepatitis C virus E2/NS1 region |
| US5514539A (en) | 1993-06-29 | 1996-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
| US5610009A (en) * | 1994-01-28 | 1997-03-11 | Abbott Laboratories | Mammalian expression systems for hepatitis C virus envelope genes |
| AU3241095A (en) * | 1994-07-29 | 1996-03-04 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| DK1510580T3 (da) | 1994-07-29 | 2009-02-16 | Novartis Vaccines & Diagnostic | Trunkeret hepatitis C E2-polypeptid og fremgangsmåder til opnåelse heraf |
| EP1845108A3 (en) | 1994-07-29 | 2007-10-24 | Innogenetics N.V. | Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| IT1271593B (it) * | 1994-11-30 | 1997-06-04 | Sanitaria Scaligera Spa | Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120. |
| US6127116A (en) | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| FR2744725B1 (fr) * | 1996-02-09 | 1998-04-30 | Pasteur Institut | Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes |
| US6514731B1 (en) | 1996-05-24 | 2003-02-04 | Chiron Corporation | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens |
| KR100209095B1 (ko) * | 1996-06-28 | 1999-07-15 | 성재갑 | C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도 |
| ATE423204T1 (de) | 1996-11-08 | 2009-03-15 | Us Gov Health & Human Serv | Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln |
| US7049428B1 (en) | 1998-03-04 | 2006-05-23 | Washington University | HCV variants |
| US7338759B1 (en) | 1997-03-04 | 2008-03-04 | Washington University | HCV variants |
| AU7471698A (en) | 1997-05-06 | 1998-11-27 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
| EP0947525A1 (en) | 1998-03-27 | 1999-10-06 | Innogenetics N.V. | Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue |
| US7108855B2 (en) | 1998-06-24 | 2006-09-19 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| KR20070114209A (ko) | 2000-08-17 | 2007-11-29 | 트리펩 아베 | 리바비린 함유 백신 및 이것의 사용 방법 |
| US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| US7101561B2 (en) | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| US20030232745A1 (en) * | 2001-06-26 | 2003-12-18 | Olson William C. | Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection |
| US7022323B2 (en) | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| CA2495680A1 (en) * | 2002-08-16 | 2004-02-26 | Bertrand Saunier | Hepatitis c viral-like particle purification |
| US7968697B2 (en) | 2005-05-25 | 2011-06-28 | Chrontech Pharma Ab | Hepatitis C virus non-structural NS3/4A fusion gene |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| WO2009130588A2 (en) | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989004669A1 (en) * | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
| IL88599A0 (en) * | 1987-12-10 | 1989-07-31 | Cell Bio Group Ltd | Glycoprotein cell growth modulating materials,their preparation and compositions containing them |
| WO1990011089A1 (en) * | 1989-03-17 | 1990-10-04 | Chiron Corporation | Nanbv diagnostics and vaccines |
| RO109916B1 (ro) * | 1990-04-04 | 1995-07-28 | Chiron Corp | Compozitie de antigeni ai hepatitei virale c |
-
1991
- 1991-11-07 HU HU9301336A patent/HU227498B1/hu unknown
- 1991-11-07 AT AT92900091T patent/ATE188220T1/de not_active IP Right Cessation
- 1991-11-07 AU AU90267/91A patent/AU668078B2/en not_active Expired
- 1991-11-07 HU HU9301336A patent/HUT66063A/hu unknown
- 1991-11-07 SK SK442-93A patent/SK285623B6/sk not_active IP Right Cessation
- 1991-11-07 SK SK690-97A patent/SK285624B6/sk not_active IP Right Cessation
- 1991-11-07 DK DK97120661T patent/DK0842947T4/da active
- 1991-11-07 SK SK40-2005A patent/SK286106B6/sk unknown
- 1991-11-07 CZ CZ1993824A patent/CZ289006B6/cs not_active IP Right Cessation
- 1991-11-07 CA CA002095521A patent/CA2095521C/en not_active Expired - Lifetime
- 1991-11-07 ES ES92900091T patent/ES2139591T5/es not_active Expired - Lifetime
- 1991-11-07 RO RO93-00626A patent/RO115446B1/ro unknown
- 1991-11-07 WO PCT/US1991/008272 patent/WO1992008734A1/en not_active Ceased
- 1991-11-07 CA CA002203443A patent/CA2203443C/en not_active Expired - Lifetime
- 1991-11-07 JP JP4500944A patent/JPH06504431A/ja active Granted
- 1991-11-07 EP EP92900091A patent/EP0556292B2/en not_active Expired - Lifetime
- 1991-11-07 DE DE69131882T patent/DE69131882T3/de not_active Expired - Lifetime
- 1991-11-07 EP EP97120661A patent/EP0842947B2/en not_active Expired - Lifetime
- 1991-11-07 DK DK92900091T patent/DK0556292T4/da active
- 1991-11-08 PT PT99466A patent/PT99466B/pt not_active IP Right Cessation
-
1993
- 1993-05-05 FI FI932025A patent/FI107803B/fi not_active IP Right Cessation
- 1993-05-07 NO NO931680A patent/NO304380B1/no not_active IP Right Cessation
-
1997
- 1997-05-14 NO NO972213A patent/NO304381B1/no not_active IP Right Cessation
- 1997-06-26 PT PT102022A patent/PT102022B/pt not_active IP Right Cessation
-
1998
- 1998-04-14 JP JP10317898A patent/JP3207155B2/ja not_active Expired - Lifetime
-
2000
- 2000-02-28 GR GR20000400473T patent/GR3032771T3/el unknown
-
2001
- 2001-03-02 JP JP2001059335A patent/JP2001286290A/ja not_active Withdrawn
-
2002
- 2002-07-08 JP JP2002199317A patent/JP4056306B2/ja not_active Expired - Lifetime
- 2002-12-04 JP JP2002353148A patent/JP2003174875A/ja not_active Withdrawn
-
2005
- 2005-02-10 JP JP2005035317A patent/JP2005187479A/ja not_active Withdrawn
-
2006
- 2006-05-25 JP JP2006145982A patent/JP2006219503A/ja not_active Withdrawn
-
2007
- 2007-10-12 JP JP2007267258A patent/JP2008031181A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2139591T3 (es) | Asialoglicoproteinas del virus de la hepatitis c. | |
| Ball et al. | Glycosaminoglycans in bovine cumulus-oocyte complexes: morphology and chemistry | |
| Dacheux et al. | Protein secretion in the epididymis | |
| Olsen et al. | Interchain disulfide bonds at the COOH-terminal end of procollagen synthesized by matrix-free cells from chick embryonic tendon and cartilage | |
| RU2009131610A (ru) | Среда для культивирования клеток без белков и без сыворотки | |
| NO2003010I2 (no) | Pegfilgrastim | |
| Katz et al. | Membrane assembly: synthesis and intracellular processing of the vesicular stomatitis viral glycoprotein | |
| KR900016261A (ko) | 독사독 폴리펩티드 및 유전적 발현 | |
| DK0531404T3 (da) | Ubiquitin-specifik protease | |
| DK162233C (da) | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii | |
| ES8802394A1 (es) | Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana. | |
| Mundall et al. | Physical and chemical characterization of vitellogenin from the hemolymph and eggs of the tobacco hornworm, Manduca sexta | |
| DE60141014D1 (de) | Verfharen zur herstellung von herpes-simplex-virus-amplikons, die resultierenden amplikons und ihre verwendung | |
| KR910021477A (ko) | 인체 단백질 c의 글리코실화 돌연변이체의 발현을 위한 벡터 및 화합물 | |
| YU172185A (en) | Process for obtaining monoclonic anti-bodies | |
| EP1054063A3 (en) | Process for the production of naturally folded and secreted proteins | |
| Handley et al. | Characterization of the collagen synthesized by cultured cartilage cells | |
| KR970002670B1 (ko) | 고양이 인터페론 및 이의 제조방법 | |
| Do Ngoc et al. | Sequence analysis of peptide fragments from the intrinsic membrane protein of calf lens fibers MP26 and its natural maturation product MP22 | |
| EP0163573B1 (en) | Site-specific proteolysis by renin | |
| MX9600380A (es) | Proceso de extraccion de proteinas periplasmicas de microorganismos procarioticos en presencia de arginina. | |
| Cantini et al. | Differential expression of adult type MHC in satellite cell cultures from regenerating fast and slow rat muscles. | |
| Acher | Molecular evolution of neurohypophyseal hormones and neurophysins | |
| Quarto et al. | Synthesis of seminal ribonuclease in isolated lobules of bull seminal vesicles | |
| Brinster et al. | Secretion of proteins by the fertilized mouse ovum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 556292 Country of ref document: ES |